Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors 28-03-2024, 17:00

TMC Announces $37 Million Strategic Investment to Advance Deep-Sea Mineral Development 12-05-2025, 19:24

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia 21-09-2024, 15:15